ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:29 UTC
-
New hope for advanced endometrial cancer: three drug combos face off
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced or recurrent endometrial cancer. The goal was to see which combination worked best to stop the cancer from growing. Participants received either paclitaxel/carboplatin/bevacizumab, paclitaxel/carbopla…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:23 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or returned and is no longer responding to standard chemotherapy. The goal is to see if this treatment shrinks tumors and how safe it is. Partici…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 11:21 UTC
-
New drug combo targets recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in people whose endometrial, ovarian, peritoneal, or fallopian tube cancer has returned. The main goal is to find the safest dose and understand side effects. About 31 particip…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:18 UTC
-
New combo therapy shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding an experimental drug (BMS-986205) to the immunotherapy nivolumab can shrink tumors or stop them from growing in people with endometrial cancer that has returned or persists. About 24 participants will receive either nivolumab alone or the combinati…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug cocktails aim to halt return of uterine cancer
Disease control OngoingThis study tests several drug combinations in 288 women whose endometrial cancer has returned or not responded to treatment. The drugs work by blocking enzymes that help cancer grow or by boosting the immune system to attack tumors. The goal is to see if these combinations can sl…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:53 UTC